Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Controlled Phase II Clinical Trial With Intradermal IMO-2125 (Tilsotolimod) in pT3-4 cN0M0 Melanoma

NCT04126876 is registered in ClinicalTrials.gov with A.J.M. van den Eertwegh as lead sponsor.

NCT NCT04126876
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04126876 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Controlled Phase II Clinical Trial With Intradermal IMO-2125 (Tilsotolimod) in pT3-4 cN0M0 Melanoma
Lead sponsor
A.J.M. van den Eertwegh
Phase
Phase 2
Overall status
Recruiting
Start date
January 22, 2020
Completion date
November 1, 2031
Enrollment
214 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

malignant melanoma